Evotec SE 6-K, filed Nov 6, 2024

Evotec SE (EVO)

6-K 2024-11-06 For: 2024-11-06

View Original

Added on April 06, 2026

About this 6-K

Evotec SE filed this 6-K on November 6, 2024.

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

	Evotec SE

	By:	/s/ Laetitia Rouxel
		Name: Laetitia Rouxel
		Title: Chief Financial Officer

In k€	*9M 2024*		*9M 2023*
Revenues¹⁾	575,739		580,113
Costs of revenues	(506,955	)	(442,729	)
Gross profit	68,784		137,384
Gross margin in %	11.9	%	23.7	%

R&D expenses²⁾	(41,128	)	(48,366	)
SG&A expenses	(138,297	)	(127,482	)
Other operating income	34,983		52,290
Other operating expense	(11,393	)	(44,655	)
Impairment of intangible assets	—		(5,131	)
Reorganization costs	(62,257	)	—
Operating income (loss)	(149,306	)	(35,960	)

*Adjusted EBITDA³⁾*	(5,971	)	50,211

in k€ except share and per share data	Nine months ended 30 September 2024		Nine months ended 30 September 2023		Three months ended 30 September 2024		Three months ended 30 September 2023
Revenue	575,739		580,113		184,890		196,278
Costs of revenue	(506,955	)	(442,729	)	(166,607	)	(158,454	)
Gross profit	68,784		137,384		18,283		37,823

Operating income (expenses)
Research and development	(41,128	)	(48,366	)	(11,874	)	(17,503	)
Selling, general and administrative expenses	(138,297	)	(127,482	)	(46,391	)	(39,290	)
Other operating income	34,983		52,290		10,750		13,804
Other operating expenses	(11,393	)	(44,655	)	(3,459	)	(7,010	)
Impairments of intangible assets	—		(5,131	)	—		(12	)
Reorganization costs	(62,257	)	—		6,199		—
Total operating income (expenses)	(218,090	)	(173,344	)	(44,776	)	(50,011	)
Operating income (loss)	(149,306	)	(35,960	)	(26,493	)	(12,187	)

Non-operating income (expense)
Gain (loss) on investment and financial instruments reevaluation	(14,788	)	(11,065	)	(6,233	)	(16,632	)
Share of profit (loss) and reevaluation of at-equity investments	(1,507	)	(11,608	)	(1,910	)	(4,459	)
Other Financial income	2,802		8,160		917		2,482
Other Financial expense	(7,282	)	(8,558	)	(1,866	)	(3,521	)
Other non-operating income (expense)	(8,029	)	2,463		(11,290	)	4,401
Total non-operating income (expense)	(28,805	)	(20,608	)	(20,381	)	(17,729	)

Net Income (loss) before taxes	(178,111	)	(56,568	)	(46,874	)	(29,916	)
Total taxes	22,872		(11,215	)	7,241		(9,039	)

Net income (loss)	(155,239	)	(67,782	)	(39,634	)	(38,955	)
Weighted average shares outstanding	177,277,605		176,910,122		177,347,294		176,935,744
Net result per share	(0.88	)	(0.38	)	(0.22	)	(0.22	)

in k€	as of 30 September 2024		as of 31 December 2023
ASSETS
Current Assets:
— Cash and cash equivalents		231,298		510,909
¾ Investments		71,976		93,203
— Trade and other receivables		97,742		98,396
— Contract assets		39,091		25,000
— Inventories		35,772		30,890
— Current tax assets		90,920		80,659
— Other current financial assets including derivatives		75,245		12,759
— Prepaid expenses and other current assets		48,632		51,345
— Assets classified as Held for Sale		7,423		—
Total current assets		698,099		903,162

Non-current assets:
— Non-current investments and other non-current financial assets		119,362		139,023
— Investments in associates and Joint ventures		4,119		3,071
— Property, plant and equipment		813,805		806,563
— Intangible assets and Goodwill		295,866		291,089
— Deferred tax assets		36,054		14,330
— Non-current tax assets		23,503		94,393
— Other non-current assets		—		837
Total non-current assets		1,292,710		1,349,306
Total assets		1,990,809		2,252,468

in k€	as of 30 September 2024			as of 31 December 2023
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
— Current financial liabilities		53,537			149,096
— Trade and other payables		69,894			134,319
— Contract liabilities		98,684			97,587
— Deferred income		8,714			10,268
— Provisions		67,680			45,165
— Current income tax liabilities		3,785			5,565
— Other current liabilities		23,901			22,572
— Liabilities classified as Held for Sale		7,423			—
Total current liabilities		333,618			464,573

Non-current liabilities:
— Non-current financial liabilities		416,514			477,112
— Deferred tax liabilities		14,052			18,137
— Provisions		27,074			16,063
— Contract liabilities		208,207			155,287
— Other non-current liabilities		22,875			1,387
Total non-current liabilities		688,721			667,987

Stockholders’ equity:
— Share capital		177,553			177,186
— Additional paid-in capital		1,451,818			1,449,654
— Retained Earnings		(631,530	)		(476,290	)
— Accumulated other comprehensive income		(29,372	)		(30,643	)
Total stockholders’ equity		968,469			1,119,908

Total liabilities and stockholders’ equity		1,990,809			2,252,468

in k€	Nine months ended 30 September 2024			Nine months ended 30 September 2023
Cash flows from operating activities:
— Net income (loss)		(155,239	)		(67,782	)
— Adjustments to reconcile net income to net cash provided by operating activities		122,992			108,754
— Change in assets and liabilities		(23,752	)		(24,476	)
Net cash provided by (used in) operating activities		(55,999	)		16,495

Cash flow from investing activities:
— Interest Received¹		3,217			3,679
— Purchase of property, plant and equipment, net		(102,266	)		(149,956	)
— Proceeds from sale of property, plant and equipment		1,592			—
— Acquisition of intangible assets and development expenditures		(4,890	)		—
— Purchase of investments in associated companies and other long-term investments and convertibles		(12,618	)		(20,202	)
— Acquisition of current investments		(8,000	)		(21,439	)
— Proceeds from sale of current investments		30,791			203,062
— Acquisitions of subsidiaries net of cash acquired		—			1,567
—Proceeds from Government Grants²		4,066			—
Net cash used in investing activities		(88,108	)		16,711

Cash flow from financing activities:
— Interest Paid¹		(4,940	)		(4,990	)
— Proceeds from loans		900			151,374
— Proceeds from option exercise		368			233
— Repayment of loans		(110,384	)		(84,775	)
— Repayment of lease obligation		(18,038	)		(12,983	)
Net cash used in financing activities		(132,095	)		48,858

Net increase (decrease) in cash and cash equivalents		(276,202	)		82,065
Exchange rate difference		(3,408	)		2,147
Cash and cash equivalents at beginning of year		510,908			415,155
Cash and cash equivalents at end of the period		231,298			499,366

*in T€*	Evotec Group 9M 2024		Evotec Group 9M 2023
Net income	(155,239	)	(67,782	)
- Interest expense (net)	4,480		398
- Tax expense	(22,872	)	11,215
- Depreciation of tangible assets	69,452		63,719
- Amortization of intangible assets	4,667		5,432
EBITDA	(99,512	)	12,982
- Impairment of intangible assets	—		5,131
- Gain (loss) on investment and financial instruments reevaluation	14,788		11,065
- Share of profit (loss) and reevaluation of at-equity investments	1,507		11,608
- Foreign currency exchange (loss) gain, net	9,800		175
- Other non-operating income, net	(1,771	)	(2,638	)
- One-Off External Cyber-related Costs	6,960		11,889
- Reorganization Costs	62,257		—
Adjusted EBITDA	(5,971	)	50,211

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners

·	Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners

·	Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers

·	New ownership committed to maintaining and growing the business